BioDelivery Sciences International, Inc. announced the closing of its previously announced agreement with Endo Pharmaceuticals, Inc. (Endo) terminating Endo's licensing of rights for BELBUCA® (buprenorphine) buccal film (CIII). As a result of the closing, the worldwide rights to BELBUCA have now been transferred back to BDSI.
1st Jan change | Capi. | |
---|---|---|
+131.89% | 770.78Cr | |
+2.67% | 99Cr | |
+46.93% | 96Cr | |
+2.39% | 67Cr | |
-.--% | 60Cr | |
-1.26% | 58Cr | |
+10.28% | 54Cr | |
-.--% | 50Cr | |
+3.47% | 47Cr |